ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the Vaccines Summit 2022 in Washington DC on October 11-13. Founder of ImmunAdd, Pi-Hui Liang, said “My team and I were delighted to attend the Vaccines Summit, an internationally renowned academic conference, where we presented a poster […]
ImmunAdd, a privately held pharmaceutical company developing a fully synthetic, rationally designed, saponin-based small molecule vaccine adjuvant, attended the BIO International Convention conference in San Diego, California, on June 13-16. Founder of ImmunAdd, Pi-Hui Liang, said, “My team and I are delighted to attend the BIO conference in San Diego, where we will show our […]
Our team was awarded the 18th National Award in the Academic Research for “the Discovery of IA05 as a Novel Saponin Adjuvant for Therapeutic Vaccine.” Our proprietary next generation saponin-based adjuvant platform has been awarded in the 18th National Award in the Academic Research.